DocGo Inc (NASDAQ:DCGO), a provider of mobile health and medical transportation services, reported its fourth quarter and full-year 2025 financial results, delivering a mixed performance against analyst expectations. The company's core business showed signs of growth, but significant one-time charges led to substantial losses, influencing early market sentiment.
Earnings vs. Estimates: A Mixed Quarter
The company's top-line performance for the quarter exceeded Wall Street's expectations, while its bottom line fell significantly short.
- Revenue: DocGo reported Q4 2025 revenue of $74.9 million, surpassing the analyst consensus estimate of approximately $71.8 million.
- Earnings Per Share (EPS): The company reported a non-GAAP EPS loss of $0.53 for the quarter, which was markedly wider than the estimated loss of $0.13.
This divergence highlights a quarter where sales execution was stronger than anticipated, but profitability was heavily impacted by other factors outlined in the earnings release.
Market Reaction and Price Action
Following the earnings release, the stock experienced notable volatility in after-hours trading, initially rising approximately 9.7%. This positive initial reaction suggests investors may be focusing on the revenue beat and management's improved guidance for 2026. However, this follows a period of weakness, with the stock down about 7.4% over the past month, indicating broader investor caution leading up to the report. The sharp after-hours move represents a significant shift in sentiment, though its sustainability will be tested during regular trading hours.
Key Takeaways from the Earnings Report
The press release framed 2025 as a "year of transition" for DocGo, marked by the deliberate wind-down of its large migrant-related service programs. This strategic shift explains the dramatic year-over-year declines in headline revenue but reveals underlying growth in its core operations.
- Strategic Pivot from Migrant Services: The decline in total revenue—from $120.8 million in Q4 2024 to $74.9 million in Q4 2025—was attributed entirely to the wind-down of migrant-related programs. Excluding this revenue, core revenue actually increased 11% year-over-year.
- Significant Non-Cash Impairments: The quarter and full year were burdened by large non-cash impairment charges, including $50 million in goodwill and $23 million in intangible assets in Q4 alone. These accounting adjustments, while not affecting cash, contributed heavily to the reported net loss of $142.3 million for the quarter and $196.4 million for the full year.
- Core Business Growth: Management highlighted strong volume growth across its "healthcare at any address" services, including care in the home, remote patient monitoring, and virtual care. Revenue from this combined business tripled in Q4 2025 compared to the prior year.
- Improved 2026 Guidance: The company raised its full-year 2026 outlook. Revenue guidance was increased to a range of $290-$310 million (from $280-$300 million), and the adjusted EBITDA loss forecast was narrowed to $5-$10 million (from $15-$25 million). CEO Lee Bienstock expressed confidence in achieving profitability in the second half of 2026.
Forward Outlook vs. Analyst Expectations
DocGo's newly issued 2026 revenue guidance of $290-$310 million sits comfortably above the current analyst sales consensus of approximately $297.2 million for the year. This upward revision appears to be a primary driver behind the positive after-hours market reaction. For the upcoming first quarter of 2026, analysts currently project a revenue of $71.9 million and an EPS loss of $0.11.
Strategic Review
A notable corporate highlight from the release is that the company has "initiated a formal process to explore strategic alternatives to maximize shareholder value." This announcement adds another layer for investors to consider regarding the company's future direction.
For a detailed look at DocGo's historical earnings and future analyst projections, you can review the earnings history and current estimates.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy, sell, or hold any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.